Industry map/Healthcare & Consumer Goods
Biotech & Regenerative Medicine industry map
Who earns the money in Biotech & Regenerative Medicine, and who keeps it. When a company spans several industries, only the relevant segment is counted.
FY2025 · 24 companies · ¥61.3B
Industry map
Companies ordered by revenue, connected by ownership (major shareholders). Arrows point from the shareholder to the investee.
- Industry size (revenue)
- ¥61.3B
- Companies
- 24
- Avg. salary（parent only）
- ¥6.5M
- Industry weather
- Rainy
YoY -6.6%
Avg. age 44.0
Takara Holdings[2531]
Takara Bio Group
- Revenue
- ¥40.3B▼10.5%
- Operating income
- -¥4.69BTurned to loss
Margin -11.6%
Whole company: Revenue ¥394.3B · Net income ¥11.7B
Avg. salary ¥7.6M · 49.8（parent only）
Kidswell Bio[4584]
- Revenue
- ¥6.59B▲29.7%
- Operating income
- -¥138.5MTurned to loss
Margin -2.1%
Avg. salary ¥9.2M · 48.6（parent only）
- Nano Holdings owns 2.0%
StemCell Institute[7096]
- Revenue
- ¥2.81B▲4.9%
- Operating income
- ¥202.7M▼51.6%
Margin 7.2%
Avg. salary ¥5.1M · 37.1（parent only）
Kohjin Bio[177A]
Tissue culture business
- Revenue
- ¥2.54B▲11.9%
- Operating income
- ¥946.5M▲23.7%
Margin 37.3%
Whole company: Revenue ¥4.94B · Net income ¥251M
Avg. salary ¥5.5M · 38.6（parent only）
ReproCELL[4978]
Research Support Business + 1 more
- Revenue
- ¥2.23B▼25.0%
- Operating income
- ¥52.6M▼93.3%
Margin 2.4%
Whole company: Revenue ¥2.23B · Net income -¥591.7M
Avg. salary ¥6.1M · 34.2（parent only）
Japan Tissue Engineering[7774]
Regenerative Medicine Business + 2 more
- Revenue
- ¥2.18B▼11.1%
- Operating income
- ¥458.5M▼34.3%
Margin 21.0%
Whole company: Revenue ¥2.18B · Net income -¥734.8M
Avg. salary ¥6.1M · 39.7（parent only）
Waqoo[4937]
Medical support
- Revenue
- ¥999M▲59.3%
- Operating income
- ¥216.1M▲237.7%
Margin 21.6%
Whole company: Revenue ¥1.96B · Net income ¥44.1M
Avg. salary ¥5.9M · 38.6（parent only）
PRISM BioLab[206A]
- Revenue
- ¥677.3M▲121.6%
- Operating income
- -¥774.5M
Margin -114.3%
Avg. salary ¥9.5M · 45.0（parent only）
DyDo GROUP HOLDINGS[2590]
DyDo Pharma
- Revenue
- ¥606M▲7475.0%
- Operating income
- -¥321M
Margin -53.0%
Whole company: Revenue ¥241.2B · Net income -¥30.3B
Avg. salary ¥8.5M · 40.8（parent only）
D.Western Therapeutics Institute[4576]
- Revenue
- ¥387.6M▼17.8%
- Operating income
- -¥619.9M
Margin -159.9%
Avg. salary ¥6.7M · 50.8（parent only）
Pharma Foods International[2929]
Bio Medical
- Revenue
- ¥331M▼30.8%
- Operating income
- -¥378M
Margin -114.2%
Whole company: Revenue ¥65.3B · Net income ¥368M
Avg. salary ¥5.5M · 39.3（parent only）
Stella Pharma[4888]
- Revenue
- ¥323.4M▼66.4%
- Operating income
- -¥749M
Margin -231.6%
Avg. salary ¥6.6M · 48.5（parent only）
※ Card revenue and operating income cover only the segment in this industry; “Whole company” shows consolidated revenue and net income.
Other companies: Cyfuse Biomedical · Cuorips · Tsubota Laboratory · Nano Holdings · Perseus Proteomics · Medrx · Shin Nippon Biomedical Laboratories · Kringle Pharma · Oncolys BioPharma · J-Holdings · CellSeed · Medinet
The weather is derived mechanically from year-over-year totals of revenue and operating income (both up = sunny, both down = rainy).
Who earns the money
Area = revenue from businesses in this industry. Color = operating margin.
Who makes a profit
Across = revenue (log scale), up = operating margin, bubble size = operating income.
Ranking and momentum
| Rank | Company (business) | Revenue | Share | Op. margin | CAGR | FCF* |
|---|---|---|---|---|---|---|
| 1 | Takara HoldingsTakara Bio Group | ¥40.3B | 65.8% | -11.6% | -12.2% | -¥4.85B |
| 2▲1 | Kidswell Bio | ¥6.59B | 10.8% | -2.1% | +43.1% | -¥1.11B |
| 3▲2 | StemCell Institute | ¥2.81B | 4.6% | 7.2% | — | -¥453.3M |
| 4▲3 | Kohjin BioTissue culture business | ¥2.54B | 4.1% | 37.3% | +15.5% | -¥271.6M |
| 5▼1 | ReproCELLResearch Support Business + 1 more | ¥2.23B | 3.6% | 2.4% | -0.0% | -¥481.7M |
| 6 | Japan Tissue EngineeringRegenerative Medicine Business + 2 more | ¥2.18B | 3.6% | 21.0% | +3.9% | -¥565.7M |
| 7▲4 | WaqooMedical support | ¥999M | 1.6% | 21.6% | — | -¥56.8M |
| 8▲6 | PRISM BioLab | ¥677.3M | 1.1% | -114.3% | +144.9% | -¥1.54B |
| 9▲15 | DyDo GROUP HOLDINGSDyDo Pharma | ¥606M | 1.0% | -53.0% | — | -¥1.28B |
| 10▲3 | D.Western Therapeutics Institute | ¥387.6M | 0.6% | -159.9% | -1.7% | -¥496.5M |
| 11▲1 | Pharma Foods InternationalBio Medical | ¥331M | 0.5% | -114.2% | -3.1% | -¥2B |
| 12▼3 | Stella Pharma | ¥323.4M | 0.5% | -231.6% | +34.1% | -¥346.2M |
| 13▲8 | Cyfuse Biomedical | ¥231M | 0.4% | -358.5% | -24.4% | -¥582.4M |
| 14▲3 | Cuorips | ¥212.3M | 0.3% | -509.2% | — | -¥1.11B |
| 15▼7 | Tsubota Laboratory | ¥200M | 0.3% | -393.9% | -25.3% | -¥586.6M |
| 16▲3 | Nano Holdings | ¥174.5M | 0.3% | -553.6% | — | — |
| 17▲1 | Perseus Proteomics | ¥135.5M | 0.2% | -549.8% | +17.2% | -¥663.3M |
| 18▼3 | Medrx | ¥128.1M | 0.2% | -735.4% | +97.9% | -¥970.9M |
| 19▲3 | Shin Nippon Biomedical LaboratoriesTranslational Research | ¥105.5M | 0.2% | -3818.2% | +72.0% | ¥2.99B |
| 20 | Kringle Pharma | ¥72.2M | 0.1% | -1259.4% | -29.3% | — |
| 21▲2 | Oncolys BioPharma | ¥28.5M | 0.0% | -7090.6% | -54.1% | -¥1.94B |
| 22new | J-HoldingsRegenerative medicine-related business | ¥6M | 0.0% | -1084.2% | — | -¥529.4M |
| 23▲2 | CellSeedCell-Sheet regenerative medicine | ¥1.9M | 0.0% | -38558.9% | — | -¥1.02B |
| 24▲3 | MedinetCellular and tissue-based product business | ¥219K | 0.0% | -186290.4% | +1.5% | -¥1.45B |
* FCF is company-wide (not disclosed by segment). CAGR covers the available years, up to five.
How they make money differently
Where each company's ¥100 of sales goes, and how much it keeps (company-wide).
- Cost of sales
- SG&A
- Operating profit
- Waqoo20728
- Shin Nippon Biomedical Laboratories50428
- StemCell Institute39547
- Kohjin Bio62317
- Takara Holdings6828
- Pharma Foods International1977
- DyDo GROUP HOLDINGS5543
- Kidswell Bio7329loss ¥2
- Japan Tissue Engineering4283loss ¥25
- ReproCELL5584loss ¥39
- PRISM BioLab60154loss ¥114
- D.Western Therapeutics Institute10250loss ¥160
- J-Holdings41223loss ¥164
- Medinet86192loss ¥178
- Stella Pharma14318loss ¥232
- Cyfuse Biomedical51408loss ¥359
- Tsubota Laboratory34460loss ¥394
- Cuorips38571loss ¥509
- Perseus Proteomics14636loss ¥550
- Nano Holdings12642loss ¥554
- Medrx834loss ¥735
- CellSeed491301loss ¥1250
- Kringle Pharma1359loss ¥1259
- Oncolys BioPharma7191loss ¥7091
Ownership links
From the major-shareholder section of annual securities reports.
- 株式会社日本トリムOutside
- SubsidiaryStemCell Institute71.2%
- 帝人株式会社Outside
- SubsidiaryJapan Tissue Engineering57.7%
- ステラケミファ株式会社Outside
- AffiliateStella Pharma33.7%
- ノーリツ鋼機株式会社Outside
- StakeKidswell Bio19.1%
- 第一三共株式会社Outside
- StakeCuorips12.1%
- 株式会社ニデックOutside
- StakeJapan Tissue Engineering10.4%
- テルモ株式会社Outside
- StakeCuorips6.4%
- 伊藤忠商事株式会社Outside
- StakePharma Foods International5.0%
- 日本化薬株式会社Outside
- StakeSolasia Pharma4.5%
- ｓａｎｔｅｃ Ｈｏｌｄｉｎｇｓ株式会社Outside
- StakePRISM BioLab3.4%
The company on each card is a major shareholder of the companies listed under it (latest 'major shareholders' disclosure). 50%+ is labelled subsidiary and 20%+ affiliate, based on ownership alone. Stakes under 3% are omitted.
Compare the leaders side by side
All companies in Biotech & Regenerative Medicine (by revenue)
All 30 companies in this industry, ranked by revenue in each company's latest fiscal year. For companies that belong through one business segment, the figure is that segment's revenue.
- Takara Holdings¥40.3B · -11.6%
- PeptiDream¥31.3B · 66.9%
- Nxera Pharma¥12.8B
- Kidswell Bio¥6.59B · -2.1%
- StemCell Institute¥2.81B · 7.2%
- Kohjin Bio¥2.54B · 37.3%
- ReproCELL¥2.23B · 2.4%
- Japan Tissue Engineering¥2.18B · 21.0%
- Waqoo¥999M · 21.6%
- Heartseed¥873.6M · -118.9%
- PRISM BioLab¥677.3M · -114.3%
- Solasia Pharma¥617M
- DyDo GROUP HOLDINGS¥606M · -53.0%
- D.Western Therapeutics Institute¥387.6M · -159.9%
- Pharma Foods International¥331M · -114.2%
- Stella Pharma¥323.4M · -231.6%
- Cyfuse Biomedical¥231M · -358.5%
- Cuorips¥212.3M · -509.2%
- Tsubota Laboratory¥200M · -393.9%
- Nano Holdings¥174.5M · -553.6%
- Perseus Proteomics¥135.5M · -549.8%
- Medrx¥128.1M · -735.4%
- Healios¥121M
- Shin Nippon Biomedical Laboratories¥105.5M · -3818.2%
- Kringle Pharma¥72.2M · -1259.4%
- Oncolys BioPharma¥28.5M · -7090.6%
- J-Holdings¥6M · -1084.2%
- CellSeed¥1.9M · -38558.9%
- BrightPath Biotherapeutics¥1.1M · -102464.1%
- Medinet¥219K · -186290.4%
Revenue · Op. margin
Related industries
Analyze this page with AI
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.